Increasing transparency and accountability in national pharmaceutical systems.

Area of Science:

• Health Policy
• Pharmaceutical Governance
• Public Health

Background:

• Poor pharmaceutical system governance compromises access to safe, effective medicines.
• Complex systems with diverse actors are vulnerable to inefficiencies and corruption.
• Transparency and accountability are critical for minimizing fraud and leakage in pharmaceutical supply chains.

Purpose of the Study:

• To provide a conceptual understanding of how transparency facilitates accountability for improved access to medicines.
• To identify essential information categories for strengthening pharmaceutical accountability.
• To inform policy-makers on actions to enhance transparency and accountability in pharmaceutical systems.

Main Methods:

• Conceptual analysis of transparency and accountability in pharmaceutical governance.
• Identification of information categories prerequisite for accountability.
• Review of experiences from the Good Governance for Medicines programme and Medicines Transparency Alliance.

Main Results:

• Stakeholder interpretations of transparency and accountability varied.
• Lack of clarity on information disclosure and its impact on accountability was identified.
• Three essential information categories for accountability were identified: standards and commitments, decisions and results, and consequences and responsive actions.

Conclusions:

• Conceptual clarity and practical examples of information needed for accountability can guide policy-makers.
• Increased transparency, supported by appropriate information, can strengthen accountability for medicine access.
• Understanding factors that hinder or facilitate information use is crucial for effective accountability mechanisms.